Last update 04 Nov 2024

Ignis Therapeutics (Suzhou) Limited

Private Company | Subsidiary Company|
2022|
Jiangsu Sheng, China
|
www.ignistherapeutics.com

Overview

Tags

Nervous System Diseases
Other Diseases
Respiratory Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Immune System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
DAT x NET x TAAR11
DRDs(Dopamine receptors)1

Related

2
Drugs associated with Ignis Therapeutics (Suzhou) Limited
Solriamfetol Hydrochloride
Target
DAT x NET x TAAR1
Mechanism
DAT antagonists [+2]
Active Org.
Axsome Therapeutics, Inc.Axsome Therapeutics, Inc. [+7]
Originator Org.
SK Biopharmaceuticals Co., Ltd.SK Biopharmaceuticals Co., Ltd.
Active Indication
Excessive Daytime Sleepiness [+9]
Inactive Indication
Neuralgia [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date20 Mar 2019
Apomorphine Hydrochloride
Target
DRDs
Mechanism
DRDs agonists
Active Org.
Laboratoire AguettantLaboratoire Aguettant [+10]
Originator Org.
STADA Arzneimittel AGSTADA Arzneimittel AG
Active Indication
Parkinson Disease [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
EU [+3]
First Approval Date28 May 2001
4
Clinical Trials associated with Ignis Therapeutics (Suzhou) Limited
NCT06103825 / RecruitingPhase 3
A Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Treatment With Solriamfetol in Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea Syndrome (OSA) With a 12-week Treatment Period
CTR20231397 / CompletedPhase 3
索安非托治疗阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思 睡（ EDS）的 治疗期12周的双盲、安慰剂对照、随机 、平行、多中心药物疗效和安全性的研究
[Translation] A 12-week double-blind, placebo-controlled, randomized, parallel, multicenter study on the efficacy and safety of Soanfitol in the treatment of excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea syndrome (OSA)
CTR20232033 / CompletedPhase 1
一项在中国健康受试者中评价单次给予盐酸阿扑吗啡注射液（皮下注射）的药代动力学特征、安全性、耐受性的I 期、开放性临床研究
[Translation] A Phase I, open-label clinical study to evaluate the pharmacokinetic characteristics, safety, and tolerability of a single dose of apomorphine hydrochloride injection (subcutaneous injection) in healthy Chinese subjects
100 Clinical Results associated with Ignis Therapeutics (Suzhou) Limited
Login to view more data
0 Patents (Medical) associated with Ignis Therapeutics (Suzhou) Limited
Login to view more data
100 Deals associated with Ignis Therapeutics (Suzhou) Limited
Login to view more data
100 Translational Medicine associated with Ignis Therapeutics (Suzhou) Limited
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Phase 3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Solriamfetol Hydrochloride
 ( DAT x NET x TAAR1 )		Excessive Daytime Sleepiness
More
Phase 3
Apomorphine Hydrochloride
 ( DRDs )		Parkinson Disease
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free